Adial Pharmaceuticals, Inc.ADILNASDAQ
Loading
EPS Growth AcceleratingAccelerating
Percentile Rank87
3Y CAGR+29.3%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
+29.3%/yr
vs -9.7%/yr prior
Acceleration
+39.0pp
Accelerating
Percentile
P87
Within normal range
vs 3Y Ago
2.2x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 55.56% |
| Q2 2025 | 47.06% |
| Q1 2025 | -209.09% |
| Q4 2024 | 71.05% |
| Q3 2024 | 35.59% |
| Q2 2024 | 73.06% |
| Q1 2024 | -90.43% |
| Q4 2023 | 2.54% |
| Q3 2023 | -222.92% |
| Q2 2023 | 135.16% |
| Q1 2023 | -1.49% |
| Q4 2022 | 8.81% |
| Q3 2022 | 25.69% |
| Q2 2022 | -33.22% |
| Q1 2022 | 58.03% |
| Q4 2021 | -30.51% |
| Q3 2021 | 13.79% |
| Q2 2021 | 16.86% |
| Q1 2021 | -25.87% |
| Q4 2020 | 1.31% |
| Q3 2020 | -52.37% |
| Q2 2020 | 26.01% |
| Q1 2020 | -11.75% |
| Q4 2019 | -16.03% |
| Q3 2019 | 19.92% |
| Q2 2019 | 35.79% |
| Q1 2019 | -70.08% |
| Q4 2018 | 87.05% |
| Q3 2018 | -438.98% |
| Q2 2018 | -245.96% |
| Q1 2018 | -7.61% |
| Q4 2017 | -37.31% |
| Q3 2017 | 2.90% |
| Q2 2017 | -48.39% |
| Q1 2017 | -86.00% |
| Q4 2016 | 7.41% |
| Q3 2016 | -8.00% |
| Q2 2016 | 24.24% |
| Q1 2016 | 0.00% |